Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.33 -0.01 (-0.23%)
price chart
Arena Pharmaceuticals Could Have Better Luck In Quarter 2 (ARNA)
New prescription numbers for week ending March 13 have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The week-to-week improvements in total (TRx) and new (NRx) prescriptions are ...
Arena Investors Need To Pay Attention To Competition
If you are invested in Arena Pharmaceuticals (NASDAQ:ARNA), some news delivered today by competitor Orexigen (NASDAQ:OREX) is something that you need to consider.
Orexigen Therapeutics Embarrasses Arena and VIVUS Again (VVUS, OREX ...  SmallCap Network
Zacks Rating Update on Arena Pharmaceuticals, Inc.
Research firm Zacks has rated Arena Pharmaceuticals (NASDAQ:ARNA) and has ranked it at 4, indicating that for the short term the shares are a sell.
Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Fourth quarter updates on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. Short Interest Disclosure  Stafford Daily
Mid-Day Buzzers � Arena Pharmaceuticals (ARNA), Marvell (MRVL), Himax ...  Techsonian (press release)
Earnings Reaction History: Arena Pharmaceuticals, Inc., 42.9% Follow-Through ...
Over the prior three fiscal years (12 quarters), when shares of ARNA rose in the extended-hours session in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock posted additional gains in the following regular ...
Arena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for ...
Arena Pharmaceuticals Inc. ($ARNA) experienced unusually high volume on Mar. 17, as the stock gained 5.27% to a closing price of $4.99.
Arena Pharmaceuticals Misses Q4 Expectations
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported financial results Monday for the fourth quarter and full year ended December 31, 2014.
Analyst Rating Update on Arena Pharmaceuticals, Inc.  Stafford Daily
Stock To Watch : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Markets Wired
Arena Pharmaceuticals Now Likely To Miss Q1 Estimates (ARNA)
New prescription numbers have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The 3.3% week-to-week improvement in total prescriptions (TRx) is a slight improvement over the previous ...
Healthcare Stocks in the Spotlight: Arena Pharmaceuticals (ARNA), Genetic ...  Techsonian (press release)
ARNA Crosses Below Key Moving Average Level
In trading on Tuesday, shares of Arena Pharmaceuticals Inc (Symbol: ARNA) crossed below their 200 day moving average of $4.54, changing hands as low as $4.50 per share.